Results 11 to 20 of about 685,052 (299)

Administration of fusion cytokines induces tumor regression and systemic antitumor immunity

MedComm, 2021
It is difficult to improve the curative effects of cancer immunotherapy on solid tumors. Cytokines, as powerful immune regulators, show potential in activating host antitumor immunity.
Jinyu Zhang, Xuan Zhao
doaj   +1 more source

Human Mesenchymal Stem Cells Overexpressing Interleukin 2 Can Suppress Proliferation of Neuroblastoma Cells in Co-Culture and Activate Mononuclear Cells In Vitro

Bioengineering, 2020
High-dose recombinant interleukin 2 (IL2) therapy has been shown to be successful in renal cell carcinoma and metastatic melanoma. However, systemic administration of high doses of IL2 can be toxic, causing capillary leakage syndrome and stimulating pro ...
Daria S. Chulpanova, Valeriya V. Solovyeva, Victoria James, Svetlana S. Arkhipova, Marina O. Gomzikova, Ekaterina E. Garanina, Elvira R. Akhmetzyanova, Leysan G. Tazetdinova, Svetlana F. Khaiboullina, Albert A. Rizvanov   +9 more
doaj   +1 more source

Interleukin‐1α, interleukin‐2, and soluble interleukin‐2 receptors in polymyositis [PDF]

Arthritis & Rheumatism, 1990
AbstractCell‐mediated immunity has been implicated in the pathogenesis of polymyositis (PM). We conducted a prospective study in which serum levels of soluble interleukin‐2 receptors (IL‐2R), IL‐1α, and IL‐2 were correlated with creatine kinase (CK) levels and clinical disease activity.
R E, Wolf, B A, Baethge
openaire   +2 more sources

Abscopal responses in patients with metastatic melanoma involving skin and subcutaneous tissues treated with intralesional IL2 plus BCG

Frontiers in Oncology, 2023
Cutaneous melanoma is relatively common with increasing incidence and significant mortality. While the mainstay of therapy is surgical, patients with stage III and IV disease fare poorer than those with early-stage disease and often benefit from adjuvant
Dejan Vidovic, Lucy Kathryn Helyer, Sylvia Pasternak, Carman Anthony Giacomantonio   +3 more
doaj   +1 more source

Impact of IL-2 on Treatment Tolerance in Patients With High-Risk Neuroblastoma Treated With Dinutuximab Beta-Based Immunotherapy

Frontiers in Pediatrics, 2020
Patients with high-risk neuroblastoma treated with continuous long-term infusion of anti-GD2 antibody dinutuximab beta (DB) in combination with IL-2 show an acceptable safety profile. Here, we compared treatment tolerance with and without IL-2.
Filiz Cicek, Sascha Troschke-Meurer, Kiraz Ceylan, Luciana J. Jahns, Maxi Zumpe, Nikolai Siebert, Karoline Ehlert, Holger N. Lode   +7 more
doaj   +1 more source

Oncolytic Adenoviruses Armed with Tumor Necrosis Factor Alpha and Interleukin-2 Enable Successful Adoptive Cell Therapy

Molecular Therapy: Oncolytics, 2017
Adoptive cell therapy holds much promise in the treatment of cancer but results in solid tumors have been modest. The notable exception is tumor-infiltrating lymphocyte (TIL) therapy of melanoma, but this approach only works with high-dose ...
Riikka Havunen, Mikko Siurala, Suvi Sorsa, Susanna Grönberg-Vähä-Koskela, Michael Behr, Siri Tähtinen, João Manuel Santos, Pauliina Karell, Juuso Rusanen, Dirk M. Nettelbeck, Anja Ehrhardt, Anna Kanerva, Akseli Hemminki   +12 more
doaj   +1 more source

Recovery of T‐cell function in healthy dogs following cessation of oral cyclosporine administration

Veterinary Medicine and Science, 2020
Cyclosporine is a potent immunosuppressive agent used to treat immune‐mediated disorders in dogs. Secondary infections sometimes necessitate withdrawal of cyclosporine, but it is not known how long it takes for the immune system to recover after ...
Lakshmi Narayanan, Charlee Mulligan, Lisa Durso, Brittany Thames, John Thomason, Claire Fellman, Andrew Mackin, Robert Wills, Todd Archer   +8 more
doaj   +1 more source

Phase II Trial of Maintenance Treatment With IL2 and Zoledronate in Multiple Myeloma After Bone Marrow Transplantation: Biological and Clinical Results

Frontiers in Immunology, 2021
BackgroundMaintenance treatment after autologous bone marrow transplantation in multiple myeloma improves the outcome of patients. We designed a phase II clinical trial to evaluate the treatment with IL2 and zoledronate after autologous bone marrow ...
Rita Fazzi, Iacopo Petrini, Nicola Giuliani, Riccardo Morganti, Giovanni Carulli, Benedetta Dalla Palma, Laura Notarfranchi, Sara Galimberti, Gabriele Buda   +8 more
doaj   +1 more source

An optimized cultivation method for future in vivo application of γδ T cells

Frontiers in Immunology, 2023
γδ T cells, with their properties of both the innate and acquired immune systems, are suitable candidates for cellular immunotherapy in cancer. Because of their non-major histocompatibility complex (MHC) binding T cell receptor, allogenic transfer is ...
Anna Bold, Heike Gross, Elisabeth Holzmann, Stefan Knop, Timm Hoeres, Timm Hoeres, Martin Wilhelm   +6 more
doaj   +1 more source

Autologous cancer cell vaccination, adoptive T‐cell transfer, and interleukin‐2 administration results in long‐term survival for companion dogs with osteosarcoma

Journal of Veterinary Internal Medicine, 2020
Background Osteosarcoma (OSA) in dogs is an aggressive bone tumor with frequent chemotherapy failure and translational relevance for human health. Hypothesis/Objectives We hypothesized that dogs with OSA could be treated safely by ex vivo activated T ...
Brian K. Flesner, Gary W. Wood, Pamela Gayheart‐Walsten, F. Lynn Sonderegger, Carolyn J. Henry, Deborah J. Tate, Sandra M. Bechtel, Lindsay L. Donnelly, Gayle C. Johnson, Dae Young Kim, Tammie A. Wahaus, Jeffrey N. Bryan, Noe Reyes   +12 more
doaj   +1 more source